Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes

Abstract

Aims: Effects of the long acting GLP-1 analogue - liraglutide in subjects with type 2 diabetes. Methods: 144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label). The dose of liraglutide was increased weekly from 0.5 to 2 mg OD. Results: Liraglutide added to metformin monotherapy was associated with a significant reduction in fasting serum glucose (FSG) (-3.9 mM -4.9; -2.9) (primary objective), and HbA1c levels (-0.8% -1.2; -0.4). Furthermore, liraglutide in combination with metformin vs. metformin plus glimepiride significantly reduced FSG (-1.2 mM -2.2; -0.2). In addition, body weight was significantly lower in the metformin plus liraglutide vs. the metformin plus glimepiride group (-2.9 kg -3.6; -2.1). There were no biochemically confirmed episodes of hypoglycaemia with liraglutide treatment. Nausea was the most frequently reported adverse event following liraglutide therapy, it was transient in nature, and led to withdrawal of only 4% of the subjects. Conclusions: Using a weekly dose-titration liraglutide is well tolerated up to 2 mg daily. While liraglutide caused transient gastrointestinal side effects, this rarely interfered with continuing treatment. An improvement in FSG over that in control groups was seen for liraglutide as an add-on to metformin. In the latter case, body weight was reduced in comparison to metformin plus glimepiride. Liraglutide is a promising drug for the treatment of type 2 diabetes.

Key words

GLP-1 - liraglutide - randomised-controlled-trial - type 2 diabetes mellitus - body weight

References

• 1 Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52- week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.  Diabetes Care. 2004;  27 2874-2880
• 2 Chang AM, Jakobsen G, Sturis J. et al . The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.  Diabetes. 2003;  52 1786-1791
• 3 DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.  Diabetes Care. 2005;  28 1092-1100
• 4 Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.  Diabetes Care. 1996;  19 849-856
• 5 Juhl CB, Hollingdal M, Sturis J. et al . Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.  Diabetes. 2002;  51 424-429
• 6 Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, doubleblind, randomized, controlled trial.  Diabetes Care. 2004;  27 1335-1342
• 7 Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA. Change in patients’ body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrolective cohort study.  Diabetologia. 2003;  46 1611-1617
• 8 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 9 Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.  BioDrugs. 2003;  17 93-102
• 10 Nauck MA, Meier JJ, Creutzfeldt W. Incretins and their analogues as new antidiabetic agents.  Drug News Perspect. 2003;  16 413-422
• 11 Saad M, An B. Santiago O on behalf of the 2072 study group . The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with Type 2 diabetes (abstract).  Diabetologia. 2002;  45 ((Suppl. 2)) A44
• 12 Sturis J, Gotfredsen CF, Rømer J. et al . GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on betacell mass dynamics.  Br J Pharmacol. 2003;  140 123-132
• 13 UK Prospective Diabetes Study Group (UKPDS) . Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 14 Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.  Lancet. 2002;  359 824-830
• 15 Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.  Diabetes Care. 2001;  24 720-725

1 on behalf of the NN2211-1499 study group

Correspondence